Artisan Partners Boosts Legend Biotech Stake by 20%

Institutional investor increases position in biotech firm's sponsored ADR shares

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Artisan Partners Limited Partnership increased its stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) by 20.1% during the third quarter, according to a recent SEC filing. The institutional investor now owns 2,547,952 shares, or about 1.38% of the company's stock, valued at $83,089,000.

Why it matters

Legend Biotech is a commercial-stage biopharmaceutical company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Artisan Partners' increased investment signals confidence in the company's growth potential and pipeline of innovative cellular therapies.

The details

According to the filing, Artisan Partners acquired an additional 425,684 shares of Legend Biotech during the third quarter, bringing its total position to 2,547,952 shares. The investment firm now owns about 1.38% of Legend Biotech's outstanding shares. Legend Biotech's lead asset is ciltacabtagene autoleucel, a BCMA-directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.

  • Artisan Partners increased its Legend Biotech stake during the 3rd quarter of 2026.

The players

Artisan Partners Limited Partnership

An institutional investment management firm that provides a range of equity investment strategies to clients worldwide.

Legend Biotech Corporation

A commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology.

Got photos? Submit your photos here. ›

The takeaway

Artisan Partners' increased stake in Legend Biotech suggests the investment firm sees significant growth potential in the biotech company's pipeline of innovative CAR-T therapies, particularly its lead asset ciltacabtagene autoleucel for multiple myeloma.